intermediate12 min read

GLP-1 and Obesity Drugs: Investor Guide

Reviewed by Blane Jackson, DDS, MBA. Educational guide only. See the editorial policy and disclosures.

The GLP-1 revolution is reshaping the pharmaceutical industry and creating one of the most exciting investment opportunities in decades. Drugs like Ozempic and Wegovy, originally developed for diabetes, have proven to be blockbuster treatments for obesity—a condition affecting over 40% of American adults. With the global obesity drug market projected to reach $100 billion by 2030, investors are scrambling to understand which companies will win. This guide will explain the science behind GLP-1 drugs in plain English, break down the current market leaders and pipeline contenders, and provide a framework for evaluating GLP-1 obesity drug stocks. Whether you're a seasoned biotech investor or just starting, you'll learn how to identify the key catalysts, risks, and opportunities in this high-growth sector.

What Are GLP-1 Drugs and Why Are They a Game-Changer?

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone in your gut that helps regulate blood sugar and appetite. When you eat, GLP-1 is released, signaling your pancreas to release insulin and your brain to feel full. GLP-1 drugs are synthetic versions of this hormone that are injected (or taken as a pill) to mimic these effects. They slow stomach emptying, reduce hunger, and increase feelings of satiety, leading to significant weight loss. The first GLP-1 drugs were developed for type 2 diabetes, but their weight-loss side effect was so pronounced that they've become a standalone treatment for obesity. The key breakthrough is that these drugs achieve weight loss comparable to bariatric surgery—15-20% of body weight—without the risks and recovery time. This has opened up a massive market: obesity is a chronic disease affecting over 650 million adults worldwide, and only a tiny fraction are currently treated with medication. The potential is enormous, and that's why investors are paying attention.

Key takeaway

GLP-1 drugs are highly effective weight-loss treatments that target a massive unmet medical need, making them a multi-billion-dollar opportunity.

Example

Novo Nordisk's semaglutide, sold as Ozempic for diabetes and Wegovy for obesity, showed 15% weight loss in clinical trials—a level previously only achievable with surgery.

The Current Market Leaders: Novo Nordisk and Eli Lilly

The GLP-1 obesity drug market is currently a duopoly. Novo Nordisk (NVO) was first to market with Wegovy (semaglutide), which received FDA approval for obesity in 2021. It's a once-weekly injection that has become a cultural phenomenon, with celebrities and even Elon Musk touting its effects. Eli Lilly (LLY) is hot on its heels with tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it targets two hormones, and it has shown even greater weight loss—up to 20-25% in trials. Both drugs are in high demand, and supply shortages have been common. These companies are investing heavily in manufacturing to meet demand. For investors, the key metrics to watch are prescription trends, supply capacity, and pricing power. Both companies have strong pipelines with next-generation drugs that could extend their lead. However, the market is large enough that multiple players can thrive, and competition is intensifying.

Key takeaway

Novo Nordisk and Eli Lilly are the clear leaders, but their dominance is not guaranteed—watch for supply, pricing, and pipeline developments.

Example

In Q3 2023, Novo Nordisk's obesity care sales grew 167% year-over-year, driven by Wegovy, while Lilly's Mounjaro sales exceeded $1 billion in its first full year.

Ready to start? Open a Webull account and trade biotech stocks commission-freevia Webull · Affiliate

The Pipeline: Who's Next in the Race?

Beyond the leaders, a wave of biotech companies are developing next-generation obesity drugs. Some are aiming for oral formulations (easier to take), others for better efficacy or fewer side effects. Key players include Amgen (AMGN) with its investigational drug AMG133, which targets GLP-1 and GIP and has shown promising early data. Pfizer (PFE) is developing oral GLP-1 drugs, though it faced setbacks with one candidate. Structure Therapeutics (GPCR) is another biotech with an oral GLP-1 drug in Phase 2. There are also companies focusing on combination therapies, such as adding other hormones like amylin or glucagon to enhance weight loss. For investors, evaluating these pipeline drugs requires understanding the clinical trial phases and data. Look for drugs that show a good balance of efficacy and safety, and consider the size of the addressable market. The key is to identify which candidates have the potential to be 'best-in-class' and which companies have the resources to bring them to market.

Key takeaway

The next wave of GLP-1 drugs could disrupt the market—keep an eye on oral formulations and combination therapies from companies like Amgen and Structure Therapeutics.

Example

Amgen's AMG133 is a once-monthly injection that in early trials showed weight loss of up to 14.5% after 12 weeks, with a favorable side effect profile.

The Investment Thesis: Why GLP-1 Stocks Could Be Long-Term Winners

The investment case for GLP-1 obesity drugs is compelling. First, the market is enormous and underpenetrated. With obesity rates rising globally, the potential patient pool is in the hundreds of millions. Second, these drugs are chronic treatments—patients typically need to stay on them to maintain weight loss, leading to recurring revenue. Third, the drugs have shown benefits beyond weight loss, including cardiovascular risk reduction, which could expand insurance coverage. Novo Nordisk's semaglutide was shown to reduce heart attack and stroke risk by 20% in a major trial, a finding that could make payers more willing to cover these expensive drugs. However, there are risks: high prices (around $1,000 per month) may limit access, and side effects like nausea and vomiting could deter some patients. Additionally, competition could drive down prices. But for long-term investors, the demographic trends and the potential for these drugs to become standard of care for obesity make this a secular growth story.

Key takeaway

GLP-1 stocks offer a rare combination of massive market potential, recurring revenue, and expanding indications, but watch for pricing pressure and side effects.

Example

Novo Nordisk's market cap surpassed $500 billion in 2023, making it Europe's most valuable company, largely on the strength of its GLP-1 franchise.

Risks and Challenges: What Could Go Wrong?

Investing in GLP-1 stocks is not without risks. The most immediate risk is supply constraints. Both Novo and Lilly have struggled to keep up with demand, leading to shortages that could frustrate patients and doctors. Manufacturing capacity is expensive and takes time to build. Another risk is safety. While GLP-1 drugs are generally well-tolerated, they can cause gastrointestinal side effects, and there are rare but serious concerns like pancreatitis and thyroid tumors (seen in animal studies). Regulatory scrutiny is also a factor—the FDA has required warnings about thyroid C-cell tumors. Additionally, the high cost of these drugs has led to debates about healthcare spending, and future pricing pressure is possible. Finally, competition could erode market share. If a more effective or more convenient drug comes along, current leaders could lose their edge. Investors should diversify across companies and stay informed about clinical trial results and regulatory decisions.

Key takeaway

Supply shortages, safety concerns, pricing pressure, and competition are the key risks that could impact GLP-1 stocks.

Example

In 2023, the FDA listed both Wegovy and Mounjaro on its drug shortage list, and some patients reported difficulty filling prescriptions.

How to Evaluate GLP-1 Obesity Drug Stocks

When evaluating GLP-1 obesity drug stocks, start by looking at the clinical data. For pipeline drugs, focus on the magnitude of weight loss, the route of administration (injection vs. oral), dosing frequency, and side effect profile. Compare these to existing treatments. Next, assess the company's financial health: cash runway, revenue growth, and profitability. For large caps like Novo and Lilly, look at their overall portfolio and pipeline. For small caps, check their cash position and upcoming milestones. Also, consider the market opportunity: is the drug targeting a niche or the broad obesity market? Finally, keep an eye on catalysts—FDA decisions, clinical trial readouts, and partnership announcements. Use resources like ClinicalTrials.gov and FDA calendars to track these events. Remember, biotech investing is risky, so never invest more than you can afford to lose and consider diversifying across multiple companies.

Key takeaway

Evaluate GLP-1 stocks on clinical data, financial health, market opportunity, and upcoming catalysts—and always diversify.

Example

When Structure Therapeutics went public in 2023, investors focused on its oral GLP-1 drug's Phase 2 data, which showed 6.2% weight loss after 12 weeks, and its cash runway to fund future trials.

Key terms

GLP-1

Glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. GLP-1 drugs mimic this hormone to treat diabetes and obesity.

Obesity

A chronic medical condition characterized by excessive body fat, defined as a BMI of 30 or higher. It increases the risk of many health problems.

Semaglutide

The active ingredient in Novo Nordisk's Ozempic and Wegovy. It is a GLP-1 receptor agonist that reduces appetite and food intake.

Tirzepatide

The active ingredient in Eli Lilly's Mounjaro and Zepbound. It is a dual GIP and GLP-1 receptor agonist, showing even greater weight loss than semaglutide.

Clinical Trial Phase

The stages of testing a drug in humans: Phase 1 (safety), Phase 2 (efficacy and side effects), Phase 3 (large-scale confirmation). FDA approval follows a successful Phase 3.

Catalyst

An event that can significantly affect a company's stock price, such as clinical trial results, FDA decisions, or partnership announcements.

Cash Runway

The length of time a company can continue operating before it runs out of cash, based on its current spending rate.

Next steps

Research the clinical trial data for Wegovy and Zepbound on ClinicalTrials.gov to understand the efficacy and safety profiles.

Follow the earnings reports of Novo Nordisk and Eli Lilly to track sales growth and supply updates.

Create a watchlist of pipeline companies like Amgen, Pfizer, and Structure Therapeutics, and set alerts for their clinical trial readouts.

Read the FDA briefing documents for upcoming advisory committee meetings on obesity drugs to gauge regulatory sentiment.

Diversify your biotech portfolio by including both large-cap leaders and small-cap pipeline plays, but never allocate more than 10% of your portfolio to speculative biotech stocks.

Put this guide to work

Use these free ClinicalInvestor tools to apply what you just learned.

2026 PDUFA Calendar →

Every FDA decision in 2026 with AI investor analysis.

Biotech Catalyst Calendar →

PDUFA dates, Phase 3 readouts, AdComs, and conferences. Free.

Trial Translator →

Paste any ClinicalTrials.gov ID and get a plain-English AI breakdown.

Biotech Screener →

Filter published biotech profiles by area, phase, market cap, and runway.

Company Profiles →

Pipelines, bull and bear cases, and next expected data for every covered biotech.

Keep learning

How to Invest in Biotech Stocks →Clinical Trial Phases Explained →How to Read Clinical Trial Data →Biotech Stock Catalysts Guide →